姚鸿｜中国药科大学｜学者主页

2026

Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond

Cong Chen, Lihua Liu, Xinnan Li, Yuning Shi, Jieya Zhou, Lijuan Huang, Liyue Zeng, Dazhi Feng, Yunyue Wang, Xinyang Nie, Quanyi Huang, Yifei Wu, Shaokang Pang, Jinyi Xu, Shengtao Xu, Hong Yao

JACS Au

DOI

2026

From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A Inhibitor Discovery

Minghui Yu, Shuangtian Tang, Lijuan Huang, Yunyue Wang, Jinyi Xu, Huajian Zhu, Hong Yao

Journal of Medicinal Chemistry

DOI

2026

ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression

Yin Yuan, Y J Lu, Xuedan Han, Yidong Zhang, Qianqian Guo, Hong Yao, Qiyi Yu, Manzhen Zhou, Xinting Huang, Hongqi Wang, Miaomiao Niu, Jun Yin, Haibo Rong, Lei Huang, Xiaoman Li, Shengtao Xu, Lufeng Zheng

Experimental & Molecular Medicine

DOI

2026

In silico studies, synthesis, and biological evaluation of novel imidazopyridine-based CYP4Z1 inhibitors targeting breast cancer stem cells

Yu Lu, Kailin Chen, Hongqi Wang, Chi Zhang, Xinting Huang, Zihan Wang, Haitao Chen, Miaomiao Niu, Hong Yao, Lufeng Zheng, Shengtao Xu, Qianqian Guo

European Journal of Medicinal Chemistry

DOI

2025

悬浮MDCK-STAT1-KO工程细胞的流感病毒生产过程研究

姚鸿，崔乃香，谭文松，赵亮，叶倩

《中国生物工程杂志》

2025

药学类新生研讨课教学思路探索与实践

徐盛涛，姚鸿，朱华健，罗姗姗，徐进宜

《药学教育》

DOI

2025

Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities

Yuning Shi, Dazhi Feng, Jieya Zhou, Lihua Liu, Xinnan Li, Zhenwei Yuan, Jianbing Wu, Hong Yao

Acta Pharmaceutica Sinica B

DOI

2025

Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo

Chen He, Junda Li, Chenxi Cui, Jia Xie, Jiajie Feng, Baixue Zhang, Xingting Huang, Rui Ma, Lufeng Zheng, Jinyi Xu, Hong Yao, Shengtao Xu

Angewandte Chemie

DOI

2025

Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer

Chenhui Ma, Li Han, Hong Yao, Wenxuan Zhao, Feihong Chen, Xiuyuan Wu, Guoqi Li, Ruimin Huang, Cheng Heng Pang, Zheying Zhu, Jinyi Xu, Guoyu Pan

British Journal of Pharmacology

DOI

2025

Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities

Jingjie Zhu, Fangyi Zhan, Jia Xie, Tonghao Fang, Yuan Sun, Feiyan Zhan, Tian Xiang Gao, J. Y. Liu, Jiajie Feng, Pijun Zhou, Huajian Zhu, Hong Yao, Zheying Zhu, Shengtao Xu, Jinyi Xu, Shengtao Xu

Bioorganic Chemistry

DOI

2025

Design, Optimization, and Biological Evaluation of a Novel Quinoline-Based POLRMT Inhibitor for Prostate Cancer Therapy

Xinnan Li, Lihua Liu, Dazhi Feng, Yuning Shi, Lijuan Huang, Minghui Yu, Xiawei Fu, Li Deng, Xinyang Nie, Cong Chen, Yifan Yuan, Moyang Guo, Chen Chen, Yongjie Zhang, Fangrong Zhang, Hong Yao

Journal of Medicinal Chemistry

DOI

2025

Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein

Shaowen Xie, Jingjie Zhu, Fangyi Zhan, Dazhi Feng, Chen He, Lihua Liu, Jia Xie, J. Y. Liu, Ming Zhong, Xingting Zhang, Jinyi Xu, Hong Yao, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2025

Nanoimmunomodulation of the Aβ-STING feedback machinery in microglia for Alzheimer’s disease treatment

Limin Tian, Guangyu Long, Siqi Zhu, Yuelong Wang, Xu Pengcheng, Lifeng Liu, Hong Yao, Shentong Fang, Shuqing Chen, Suxin Li

Proceedings of the National Academy of Sciences

DOI

2025

Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

Dazhi Feng, Xinnan Li, Junkai Liu, Xiao Shao, Lihua Liu, Yuning Shi, Yunyue Wang, Minghui Yu, Shuangtian Tang, Li Deng, Yongjie Zhang, Shaowen Xie, Jinyi Xu, Shengtao Xu, Hong Yao

Chemical Science

DOI

2024

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

Shaowen Xie, Jingjie Zhu, Yihan Peng, Fangyi Zhan, Feiyan Zhan, Chen He, Dazhi Feng, Jia Qing Xie, Jingyu Liu, Huajian Zhu, Hong Yao, Jinyi Xu, Zhigui Su, Shengtao Xu

Angewandte Chemie

DOI

2024

Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors

Jinlong Li, Tong Zhang, Di Wu, Chen He, Haoxiang Weng, Tiandong Zheng, Jie Liu, Hong Yao, Jichao Chen, Yansong Ren, Zheying Zhu, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2024

Identification of 6-Fluorine-Substituted Coumarin Analogues as POLRMT Inhibitors with High Potency and Safety for Treatment of Pancreatic Cancer

Shengnan Zhou, Xiaotong Ze, Dazhi Feng, Lihua Liu, Yuning Shi, Minghui Yu, Lijuan Huang, Yunyue Wang, Hanlu Men, Jianbing Wu, Zhenwei Yuan, Mengze Zhou, Jinyi Xu, Xinnan Li, Hong Yao

Journal of Medicinal Chemistry

DOI

2024

Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension

Peng Wang, Huajian Zhu, Jia‐Sheng Tian, Wenjian Zhu, Shengtao Xu, Hong Yao, Jie Liu, Zheying Zhu, Chao‐Yu Miao, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2024

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Chen He, Junkai Liu, Junda Li, Hongyu Wu, Chenyang Jiao, Xiaotong Ze, Shengtao Xu, Zheying Zhu, Wenjie Guo, Jinyi Xu, Hong Yao

Journal of Medicinal Chemistry

DOI

2023

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Shi Qiu, Ying Cai, Hong Yao, Chun-Sheng Lin, Yi-Qiang Xie, Song-Qi Tang, Aihua Zhang

Signal Transduction and Targeted Therapy

DOI

2023

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation

Shaowen Xie, Jingjie Zhu, Junda Li, Feiyan Zhan, Hong Yao, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2023

Controlled release of MT-1207 using a novel gastroretentive bilayer system comprised of hydrophilic and hydrophobic polymers

Napoleon-Nikolaos Vrettos, Peng Wang, Yuhan Wang, Clive J. Roberts, Jinyi Xu, Hong Yao, Zheying Zhu

Pharmaceutical Development and Technology

DOI

2023

Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase

Xinnan Li, Xiaotong Ze, Shengnan Zhou, Zhaoxin Hu, Chen He, Yilin Jia, Lihua Liu, Tao Wang, Junda Li, Shengtao Xu, Dong‐Hua Yang, Zhe‐Sheng Chen, Hequan Yao, Jinyi Xu, Hong Yao

Journal of Medicinal Chemistry

DOI

2023

Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation

Shaowen Xie, Feiyan Zhan, Jingjie Zhu, Yuan Sun, Huajian Zhu, Jie Liu, Jian Chen, Zheying Zhu, Dong‐Hua Yang, Zhe‐Sheng Chen, Hong Yao, Jinyi Xu, Shengtao Xu

Angewandte Chemie

DOI

2022

Current development of bicyclic peptides

Dazhi Feng, Lihua Liu, Yuqi Shi, Pian Du, Shengtao Xu, Zheying Zhu, Jinyi Xu, Hong Yao

Chinese Chemical Letters

DOI

2022

Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin

Xiang Ni, Chen He, Yilin Jia, Xiuyuan Wu, Kunyu Zhou, Shengtao Xu, Jinyi Xu, Hong Yao

Bioorganic & Medicinal Chemistry

DOI

2022

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Yulin Liu, Giuseppe Uras, Itse Onuwaje, Wenlong Li, Hong Yao, Shengtao Xu, Xinuo Li, Xinnan Li, James B. Phillips, Stephanie Allen, Qi Gong, Haiyan Zhang, Zheying Zhu, Jie Liu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2022

Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin

Junkai Liu, Shaowen Xie, Xiao Hong Shao, Songtao Xue, Pian Du, Hongyu Wu, Shengtao Xu, Zhe‐Sheng Chen, Dong‐Hua Yang, Jinyi Xu, Hong Yao

European Journal of Medicinal Chemistry

DOI

2021

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Shengtao Xu, Hong Yao, Yangyi Qiu, Manzhen Zhou, Dahong Li, Liang Li Wu, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2021

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2021

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease

Hong Yao, Giuseppe Uras, Pengfei Zhang, Shengtao Xu, Ying Yin, Jie Liu, Shuai Qin, Xinuo Li, Stephanie Allen, Renren Bai, Qi Gong, Haiyan Zhang, Zheying Zhu, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2021

Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities

Huajian Zhu, Wenlong Li, Shuai Wen, Yang Liu, Li-Mei C. Yang, Yuchen Tan, Tiandong Zheng, Hong Yao, Jinyi Xu, Zheying Zhu, Dong‐Hua Yang, Zhe‐Sheng Chen, Shengtao Xu

European Journal of Medicinal Chemistry

DOI

2021

In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207

Napoleon-Nikolaos Vrettos, Peng Wang, Yan Zhou, Clive J. Roberts, Jinyi Xu, Hong Yao, Zheying Zhu

Pharmaceutical Development and Technology

DOI

2020

Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer

Hong Yao, Shaowen Xie, Xiaoqian Ma, Junkai Liu, Hongyu Wu, Aijun Lin, Hequan Yao, Dahong Li, Shengtao Xu, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2020

Corrigendum to “Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors” [Eur. J. Med. Chem. 197 (2020) 112308]

Shuai Wen, Xinnan Li, Wenlong Li, Feijie Xu, Lixue Lu, Hong Yao, Li-Mei C. Yang, Huajian Zhu, Shengtao Xu, Zheying Zhu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2020

Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors

Shuai Wen, Xinnan Li, Wenlong Li, Feijie Xu, Lixue Lu, Hong Yao, Li-Mei C. Yang, Huajian Zhu, Shengtao Xu, Zheying Zhu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2020

Organocatalytic 1,5-trifluoromethylthio-sulfonylation of vinylcyclopropane mediated by visible light in the water phase

Junkai Liu, Hong Yao, Xinnan Li, Hongyu Wu, Aijun Lin, Hequan Yao, Jinyi Xu, Shengtao Xu

Organic Chemistry Frontiers

DOI

2019

Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors

Hong Yao, Feijie Xu, Guangyu Wang, Shaowen Xie, Wenlong Li, Hequan Yao, Cong Ma, Zheying Zhu, Jinyi Xu, Shengtao Xu

European Journal of Medicinal Chemistry

DOI

2019

Controllable thioester-based hydrogen sulfide slow-releasing donors as cardioprotective agents

Hong Yao, Shanshan Luo, Junkai Liu, Shaowen Xie, Yanpeng Liu, Jinyi Xu, Zheying Zhu, Shengtao Xu

Chemical Communications

DOI

2018

Discovery of Novel Quinoline–Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity

Wenlong Li, Feijie Xu, Shuai Wen, Honghao Sun, Hong Yao, Cong Ma, Shengtao Xu, Hequan Yao, Zheying Zhu, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2018

Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain

Wenlong Li, Ying Yin, Shuai Wen, Feijie Xu, Hong Yao, Jie Liu, Keguang Cheng, Jinyi Xu, Zheying Zhu, Shengtao Xu

Bioorganic Chemistry

DOI

2018

Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies

Hong Yao, Guoxiang Wei, Yanpeng Liu, Hequan Yao, Zheying Zhu, Wen‐Cai Ye, Xiaoming Wu, Jinyi Xu, Shengtao Xu

ACS Medicinal Chemistry Letters

DOI

2018

Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization

Wenlong Li, Shuai Wen, Feijie Xu, Honghao Sun, Shengtao Xu, Hong Yao, Jie Liu, Hequan Yao, Zheying Zhu, Jinyi Xu

ACS Medicinal Chemistry Letters

DOI

2018

Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities

Wenlong Li, Ying Yin, Hong Yao, Shuai Wen, Honghao Sun, Shengtao Xu, Jie Liu, Hequan Yao, Zheying Zhu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2017

6,7-Seco- ent -Kauranoids Derived from Oridonin as Potential Anticancer Agents

Shengtao Xu, Hong Yao, Mei Ying Hu, Dahong Li, Zheying Zhu, Weijia Xie, Hequan Yao, Liang Li Wu, Zhe‐Sheng Chen, Jinyi Xu

Journal of Natural Products

DOI

2017

Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation

Shengtao Xu, Hong Yao, Lingling Pei, Mei Ying Hu, Dahong Li, Yangyi Qiu, Guangyu Wang, Liang Wu, Hequan Yao, Zheying Zhu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2017

A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway

Shengtao Xu, Hong Yao, Hong Yao, Shanshan Luo, Yunkai Zhang, Dong‐Hua Yang, Dahong Li, Guangyu Wang, Mei Hu, Yangyi Qiu, Xiaoming Wu, Hequan Yao, Hequan Yao, Weijia Xie, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2016

The structural modification of natural products for novel drug discovery

Hong Yao, Junkai Liu, Shengtao Xu, Zheying Zhu, Jinyi Xu

Expert Opinion on Drug Discovery

DOI

2016

N-Heterocyclic Carbene Catalytic [4 + 2] Cyclization of 3-Alkylenyloxindoles with Enals: γ-Carbon Activation for Enantioselective Assembly of Spirocarbocyclic Oxindoles

Hong Yao, Yu Zhou, Xia Chen, Pengfei Zhang, Jinyi Xu, Hong Liu

The Journal of Organic Chemistry

DOI

2016

Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies

Shengtao Xu, Guangyu Wang, Yan Lin, Yanju Zhang, Yanju Zhang, Lingling Pei, Hong Yao, Mei Ying Hu, Yangyi Qiu, Zhangjian Huang, Yihua Zhang, Yihua Zhang, Jinyi Xu

Bioorganic & Medicinal Chemistry Letters

DOI

2016

Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria

Shengtao Xu, Shanshan Luo, Hong Yao, Hao Cai, Xiaoming Miao, Fang Wu, Dong‐Hua Yang, Xiaoming Wu, Weijia Xie, Hequan Yao, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2014

Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives

Shengtao Xu, Lingling Pei, Dahong Li, Hong Yao, Hao Cai, Hequan Yao, Xiaoming Wu, Jinyi Xu

Fitoterapia

DOI

2014

Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives

Shengtao Xu, Dahong Li, Lingling Pei, Hong Yao, Chengqian Wang, Hao Cai, Hequan Yao, Xiaoming Wu, Jinyi Xu

Bioorganic & Medicinal Chemistry Letters

DOI

精选作品

期刊论文

Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond

From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A Inhibitor Discovery

ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression

In silico studies, synthesis, and biological evaluation of novel imidazopyridine-based CYP4Z1 inhibitors targeting breast cancer stem cells

悬浮MDCK-STAT1-KO工程细胞的流感病毒生产过程研究

药学类新生研讨课教学思路探索与实践

Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities

Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo

Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer

Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities

Design, Optimization, and Biological Evaluation of a Novel Quinoline-Based POLRMT Inhibitor for Prostate Cancer Therapy

Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein

Nanoimmunomodulation of the Aβ-STING feedback machinery in microglia for Alzheimer’s disease treatment

Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors

Identification of 6-Fluorine-Substituted Coumarin Analogues as POLRMT Inhibitors with High Potency and Safety for Treatment of Pancreatic Cancer

Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation

Controlled release of MT-1207 using a novel gastroretentive bilayer system comprised of hydrophilic and hydrophobic polymers

Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase

Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation

Current development of bicyclic peptides

Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease

Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities

In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207

Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer

Corrigendum to “Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors” [Eur. J. Med. Chem. 197 (2020) 112308]

Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors

Organocatalytic 1,5-trifluoromethylthio-sulfonylation of vinylcyclopropane mediated by visible light in the water phase

Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors

Controllable thioester-based hydrogen sulfide slow-releasing donors as cardioprotective agents

Discovery of Novel Quinoline–Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity

Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain

Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies

Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization

Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities

6,7-Seco- ent -Kauranoids Derived from Oridonin as Potential Anticancer Agents

Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation

A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway

The structural modification of natural products for novel drug discovery

N-Heterocyclic Carbene Catalytic [4 + 2] Cyclization of 3-Alkylenyloxindoles with Enals: γ-Carbon Activation for Enantioselective Assembly of Spirocarbocyclic Oxindoles

Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies

Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria

Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives

Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives